The study compared estimated creatinine clearance (eCrCl) between the Cockcroft-Gault (CG) equation and the Jelliffe, Chiou, and Brater equations designed for estimation in dynamic renal function and resulting antimicrobial dosing concordance of five antimicrobials (cefepime, meropenem, piperacillin/tazobactam, vancomycin, and fluconazole) commonly used in the intensive care unit (ICU).
R enal function estimation, an important aspect of drug dosing, is complicated by acute kidney injury (AKI) in critically ill patients. The incidence of AKI in critically ill patients is estimated to range between 28.5% and 35.5% when applying Acute Kidney Injury Network criteria. 1 To estimate renal function for drug dosing, the Cockcroft-Gault (CG) equation is commonly used as a standard in Food and Drug Administration (FDA)-approved dosing recommendations in labeling by manufacturers. 2 The CG formula was developed and validated in adult men, with stable renal function limiting the precision of renal dosing adjustment in critically ill patients with dynamic renal function. 3 Other formulas including the Modification of Diet in Renal Disease Study equation and the Chronic Kidney Disease Epidemiology Collaboration formulas were developed to estimate glomerular filtration rate (eGFR) in patients at risk for chronic kidney disease (CKD). [4] [5] [6] These formulas have proven to be more accurate estimates of true GFR, and when compared with CG they offer significant
• Precision of renal dosing adjustment in patients with changing renal function is limited with the Cockcroft-Gault formula derived in stable renal function.
• Estimations of creatinine clearance by Jelliffe, Chiou, and Brater equations were proposed to monitor rapidly changing (improving or declining) renal function in all types of patients using two different time points of serum creatinine values.
• We hypothesized that the differences in creatinine clearance estimates between the Cockcroft-Gault formula and candidate formulas would affect dosing regimens of antimicrobials in intensive care unit patients with acute kidney injury.
differences in dosing recommendations. The National Kidney Disease Education Program recommends the use of any of these equations for estimates of drug dosing. 7 These methods are still limited to stable renal function, because similar to the CG formula, they include a single serum creatinine (SCr) value to estimate renal function. Some experts have recommended the use of a measured creatinine clearance (CrCl), which can be logistically challenging in many settings and often is not performed relative to the incidence of AKI. 8 In clinical pharmacy practice, renal dose adjustment of antimicrobials is a common intervention to maximize efficacy and minimize toxicity. 9 Sub-or supratherapeutic concentrations secondary to inappropriate dosing can have a negative impact on clinical and economic outcomes. 9 Given the limitations in renal function estimation formulas, alternative methods for estimating CrCl in dynamic renal function for the purposes of drug dosing are needed. Jelliffe, Chiou, and Brater equations were developed to monitor and estimate CrCl in patients with rapidly changing (improving or deteriorating) renal function ( Fig. 1) . [10] [11] [12] In 1972, Jelliffe and Jelliffe developed a computer program for the calculation of CrCl from more than one value of unstable SCr based on a dynamic model. 10 The model used the relation: daily change in the total amount of creatinine in the patient's body equates to the difference between production and excretion during that day. 10 In 1975, Chiou and Hsu proposed an equation to monitor renal function status by measuring the SCr at two different times without the necessity of urine collection using linear single-compartment pharmacokinetics. 11 Based on the data from Wheeler and Sheiner and Chiou and Hsu, Brater derived a formula for calculating CrCl when renal function is unstable. 12 Data regarding impact on drug dosing are limited to a single unpublished study that indicated a statistically significant difference in estimated CrCl (eCrCl) between the CG equation and the Jelliffe, Chiou, and Brater equations in medical intensive care unit (ICU) patients receiving antimicrobials. 13 Given the general lack of data in critically ill patients with AKI outside the medical ICU, our study aimed to compare the three candidate renal function estimation formulas (Jelliffe, Chiou, and Brater) with the CG equation and to evaluate renal dosing regimens of five commonly used antimicrobials.
Methods

Data Source
Data were analyzed from the electronic medical records of a large tertiary care and Level 1 trauma center in Columbia, South Carolina. The electronic health record is managed by the Cerner system (Cerner Corporation, North Kansas City, MO). It maintains all patient demographic, laboratory, and provider records, and allowed investigators to identify the study population.
Patient Selection
This was a retrospective observational study approved as exempt by the local institutional review board. All individuals aged 18 years or older who had a diagnosis of AKI identified by International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes 584.5, 584.6, 584.7, 584.8, 584.9, either on admission to or during a hospital stay in the postcardiovascular surgery unit, surgical trauma ICU, cardiology critical care unit, or surgical stepdown unit from January 1, 2008 through December 31, 2012, were eligible for inclusion. Only the first admission of patients with multiple hospital admissions with an AKI diagnosis was included. Patients receiving any form of renal replacement therapy were excluded. Patients with only one SCr value recorded also were excluded because of the inability to estimate renal function with the Jelliffe, Chiou, and Brater equations.
Data Collection
Data, including patient demographics (age, sex, height, weight, and race), comorbidities (preexisting CKD, sepsis, cardiac failure, and diabetes mellitus), three SCr values, and time intervals between the SCr values, were extracted from the electronic health record. SCr values included a peak value; one measure before and one measure after the peak value, if available, and time intervals in hours elapsed between each value. Five commonly used antimicrobials were selected as model medications to assess concordance in dosing recommendations: cefepime, meropenem, piperacillin/tazobactam, vancomycin, and fluconazole. Patients may not have received each of these antimicrobials during the index admission because the intent was to assess projected differences in dosing recommendations.
Outcomes
The primary outcomes of the study were difference in eCrCl and discordance of antimicrobial dosing regimens between the reference CG equation and the candidate Jelliffe, Chiou, and Brater equations. Using these equations, the eCrCls were calculated respectively and then the differences in eCrCl were compared. Antimicrobial dosing regimens were based on those recommended in the FDA-approved manufacturers' labeling, [14] [15] [16] [17] except for vancomycin, the regimen of which was based on the local institution's dosing guideline (internal availability only). Vancomycin dosing was to target a trough concentration of 15 to 20 μg/mL for severe, invasive, or a deep-seated infection (or all 3) and a concentration of 10 to 15 μg/mL for other infections such as cellulitis as reflected in consensus guidelines at the time of our study. 18 The reference dosing regimen was based on the eCrCl using the CG formula (reference equation). This reference was chosen because it is a standard used in manufacturers' labeling. Adjustment in dosing regimens was determined by the eCrCl using candidate equations and referred back to the manufacturer labeling for dose selection. We offer an example using cefepime: If the CG equation resulted in an eCrCl of 25 mL/min, then the dosing regimen was based on eCrCl between 10 and 30 mL/min. Comparatively, if the Chiou equation resulted in an eCrCl of 33 mL/min, then the dosing regimen would be based on an eCrCl between 30 and 60 mL/min. Compared with the CG regimen, if the candidate formula results in an altered dosing recommendation, then the comparison was defined as discordant. If no regimen adjustment was needed, then the comparison among formulas for the dosing recommendation was defined as concordant. Positive discordance was defined as either an increased dose or a decreased dosing interval or both when comparing candidate equations with CG. Negative discordance was defined as either a decreased dose, an increased dosing interval, or both when comparing candidate equations with CG. Discordance was measured in both the declining and improving phases of renal function. Subset analyses were conducted to examine differences in the concordance rate based on select patient demographics (eg, age, weight, race, sex) and select comorbidities.
Data Analysis
Descriptive statistics were used to summarize patient characteristics. Analysis of variance tests with repeated measures followed by the Student-Newman-Keuls method were performed to examine differences in eCrCl between reference and candidate equations. Bowker's tests of symmetry were applied to compare the dosing regimen discordance between CG and candidate equations. Subgroup analyses were conducted for obese and for older patients, respectively. Logistic regressions were applied to identify significant predictors associated with the likelihood of dosing regimen discordance (CG vs candidate equations) adjusting for age, body mass index (BMI), race, sex, and comorbidities (CKD, cardiac failure, and diabetes mellitus). The statistical significance level was defined at P < 0.05. All of the analyses were conducted using SAS 9.3 (SAS Institute, Cary, NC). All of the outcomes were assessed in declining and improving phase of renal function, respectively.
Results
A total of 387 individuals, 18 years or older in the hospital database and who met study inclusion/exclusion criteria, were identified between January 1, 2008 and December 31, 2012. Of these patients, 238 (61.5%) were aged 65 years or older, 180 (46.5%) were obese, 145 (37.5%) had comorbid CKD, and 209 (54%) developed AKI in the cardiology critical care unit (Table 1) .
Detailed primary study outcomes of discordance in eCrCl and dosing between CG and candidate formulas are displayed in Figs. 2 and 3. For the declining phase of renal function, the eCrCl calculated by the Brater equation (26.1 mL/min) was significantly different from that calculated by the CG equation (32 mL/min, P < 0.001; Fig. 2 ). The dosing regimen discordance rates between candidate equations and CG for the declining stage of renal function varied from 1% to 25%. The discordance of the antimicrobial dosing regimen was statistically significant for all five antimicrobials between CG and candidate equations except when comparing CG with Chiou and CG with Brater for both fluconazole and vancomycin (Fig. 3) . For improving renal function, significant differences in eCrCls between CG (43 mL/min) and three candidate equations (47.9 mL/min for the Brater equation, 31.7 mL/min for the Chiou equation, and 55.3 mL/min for the Jelliffe equation) were observed (P < 0.001; Fig. 2 ). In addition, dosing regimens were significantly different (CG vs three candidate equations) for all five antimicrobials, with the discordance rates ranging from 8.3% to 39.0% in this stage.
Subgroup analysis showed a similar trend of eCrCl and regimen discordance between CG and the three candidate equations in obese and older patients. The trend of the differences in eCrCls between the CG and three equations were similar (P > 0.05) for declining stage of renal function and the differences in eCrCl were significantly different for improving renal function (P <0.001) for the two subpopulations (Figs. 4 and 5) . For the improving phase of renal function, the dosing regimens were different between CG and three candidate equations for all five antimicrobials, with the discordance rates ranging from 10.6% to 48.9% in obese patients (P < 0.001) and from 8.0% to 41.6% in older adult patients (P < 0.001; Figs. 6 and 7) . For the declining phase of renal function, only the discordance of dosing regimens between CG versus Brater or Chiou for fluconazole or vancomycin was not statistically significant (P > 0.05) in obese patients (Fig. 6) . The discordance of regimens between CG and three candidate equations for vancomycin dosing was not statistically significant (P > 0.05) in older adult patients (Fig. 7) . Tables 2 and 3 , sex affected the dosing regimen discordance between the CG and Chiou equations, and BMI was a significant predictor for the dosing regimen discordance between the CG and Jelliffe equations. For the declining stage of renal function (Table 2) , logistic regression results showed that the dosing regimen discordance between the CG and Chiou equations was 2.24 (2.22-8.08) to 4.17 (2.10-8.28) times more likely to be observed in women than in men if patients received cefepime, meropenem, piperacillin/tazobactam, or vancomycin. The odds of discordance between the CG and Jelliffe equations in obese patients were 2.65 (1.17-6.03) times the odds in normalweight patients if patients received piperacillin/tazobactam. For improving renal function (Table 3) , the likelihood of dosing regimen discordance (CG vs Jelliffe) in obese patients was 2.92 (1.57-5.46) to 3.98 (1.67-9.52) times that of normal-weight patients if cefepime, fluconazole, or meropenem was administered.
As shown in
Discussion
Our study addressed an important issue of dose discordance in critically ill patients with AKI. We found that eCrCl means can be different between CG and candidate equations in both In current practice, clinicians are left with unreliable formulas developed for use in stable renal function, including CG to estimate CrCl in patients with dynamic renal function. It is possible that patients with dynamic renal function could receive less than optimal regimens. Our study explored this question and indicated that in declining renal function, the eCrCls were similar for CG and three candidate equations. In the recovery phase of renal function, however, significant differences in eCrCls were shown between CG and all of the candidate equations, suggesting potentially inappropriate dosing regimens for critically ill patients. The discordance rates of dosing regimens (CG vs three candidate equations) confirmed that suboptimal dose regimens could occur in 15% to 40% of patients if receiving cefepime, meropenem, or piperacillin/tazobactam. Optimal dosing regimens of antimicrobials for critically ill patients are important. 19 A subtherapeutic antimicrobial drug concentration can be associated with increased drug resistance, untreated infections, or potentially worsening infections. 20 Conversely, supratherapeutic antimicrobial concentrations can increase drug toxicity and prolong hospital length of stay. 21 Elevated cefepime plasma concentrations are correlated with neurological toxicity in mild renal dysfunction, manifested by altered mental status, hallucinations, or myoclonia, which can be life threatening. 21 Piperacillin/tazobactam and meropenem are linked to known renal and neurological toxicities, respectively, although the correlation to serum concentrations has not been fully established. 22, 23 As such, using Jelliffe, Chiou, or Brater equations proposed for patients with changing renal function could be a more appropriate strategy to improve the accuracy of antimicrobial dosing regimens for critically ill patients with a diagnosis of AKI when it is not possible to obtain a measured 24-hour CrCl. 8 Although recommended by some experts, 24-hour measured CrCl is cumbersome and infrequently used in clinical practice. 8 Given the current evidence, it would be challenging for a clinician to determine the optimal dosing regimen for patients using the Jelliffe, Chiou, or Brater equations. The present study begins to provide evidence for the need for additional data on the estimation of renal function in patients with AKI and the need for better methods of drug dosing. Areas for future research to help answer these questions are needed in several aspects. More data are needed to further test the validity of the three candidate equations for eCrCl, given the limited evidence for their estimates in actual patients. Additional prospective research can use computer simulation to correlate the candidate antimicrobial dosing regimens with pharmacokinetics and pharmacodynamics of antimicrobials in patients with changing renal function. Future studies may include investigation of the association between the dosing regimens from the candidate equations and pharmacokinetics and clinical outcomes. These data from future research can provide evidence to help clinicians select appropriate equations to estimate and individualize dosing regimens by incorporating patient demographics and clinical conditions. Our findings should be interpreted in the light of some limitations. First, all of the antimicrobials were hypothetically used for the study population and only highlight the potential for changes in antimicrobial dosing. As mentioned above, future studies using these formulas for dose calculation in hospitalized patients are needed to confirm the results from projected medication use. In addition, compared with the CG equation, the three equations were developed based on small populations and have not been investigated elsewhere for drug dosing. The generalizability of these three equations could limit their use in patients with various clinical conditions. It remains to be determined whether the three equations are suitable for all patients with dynamic renal function or only for those with specific clinical conditions. Although our study showed discordance of the dosing regimens, further studies are needed to assess whether the regimens based on the three candidate formulas are more effective or safer than CG for critically ill patients with dynamic renal function. Moreover, the differential dosing regimens between these three equations should be evaluated. In addition, eCrCl between CG and the three formulas were obtained by using different mathematical equations; future studies are warranted to compare our results against a gold standard estimated glomerular filtration rate.
The patient population used in this study came from a single hospital, which can only reflect the characteristics of patients admitted to the ICUs in this health system. Further evidence based on a larger population-based study is needed to examine the application of these equations to estimate antimicrobial dosing regimens. Lastly, in studies based on ICD-9 diagnostic codes, defining acute kidney disease, such as AKI or acute renal failure can be challenging for researchers, physicians, and coders. For instance, Molnar et al conducted a population-based retrospective cohort study using healthcare administrative and laboratory databases to assess the validation of administrative database codes for AKI patients. 24 They found that the most sensitive coding algorithm had a sensitivity of 42.1% (95% confidence interval 31.7-53.3), a specificity of 90.6% (95% confidence interval 87.6-93.0), and a positive likelihood ratio of 4.5. 24 Because our study included all patients with AKI based on ICD-9 codes, however, their impact on the comparisons of different equations should be minimal if we assume that this misclassification is random. Until clearer diagnostic criteria are available and used, the ICD-9 codes are still reasonable methods for capturing and defining the study sample. Our study was conducted before institution of the ICD-10th Revision coding.
Conclusions
This study explored the application of three equations derived from dynamic renal function to estimate dosing regimens. In critically ill patients with AKI, the discordance of commonly used antimicrobial dosing regimens using CG based on stable renal function and Jelliffe, Chiou, or Brater equations based on dynamic renal function was demonstrated. Additional data are needed regarding the use of these estimates in drug dosing, and we propose that further research in this area be pursued. At present, clinicians may consider the limitations of the CG equation when using FDA-approved manufacturer labeling to select an antimicrobial dosing regimen for patients with dynamic renal function to optimize drug safety and improve treatment outcomes. Only antimicrobials exhibiting significant discordance between formulas were included for evaluation. BMI, body mass index; CCU, coronary care unit; CG, Cockcroft-Gault; CI, confidence interval; CKD, chronic kidney disease; CVICU, cardiovascular intensive care unit; OR, odds ratio; SSU, surgical stepdown unit; STICU, surgical trauma intensive care unit.
